ERBB2 and sarcoma: Additionally, researchers sought to determine the maximum safe dose of HER2-CAR-T cells through clinical trial NCT00902044, assessing their potential benefit for patients with sarcoma and the safety of HER2-CAR-T cell therapy following lymphatic depletion chemotherapy.